Agilon Health
NYSE: AGL
$129.60 ▲ +8.38  (+6.91%)
At close: Jul 17, 2026 · 3:59 PM UTC
Financial Ratios
Market Cap1.86 Bn
P/E98.02
P/S0.32
Div. Yield0.00
ROIC (Qtr)-0.02
Total Debt (Qtr)30.03 Mn
Revenue Growth (1y) (Qtr)-7.33
Add ratio to table…

About

agilon health, inc. empowers primary care physicians to act as agents of change in their communities by providing a platform that supports a Medicare centered globally capitated model of care. The company forms risk bearing entities that contract with health plan payors to receive monthly payments for managing the total health care needs of attributed patients. Through long term partnerships with existing physician groups agilon health, inc. supplies technology people…

Read more ↓
Sector: Healthcare Industry: Medical Care Facilities CIK: 0001831097

Investment Thesis

▲ Bull case
  • The company has strengthened its data pipeline giving it direct payer feeds for about 85% of members which enables earlier risk score validation and better revenue capture. This improved visibility allowed management to raise its full year risk score uplift estimate to 1.5% net of V28 impact up from 0.4% earlier. The higher risk scores translate into additional medical margin that is already flowing through the quarter and should continue to support earnings throughout 2026. Investors may be underestimating the durability of this uplift as the pipeline continues to mature and deliver more granular insights. As the data pipeline integrates more clinical encounter information the ability to predict member health needs will improve. This predictive edge can lead to proactive interventions that lower unnecessary utilization and boost margin over time.
  • A new full risk payer contract signed in an existing market is modeled at roughly 200 million dollars of revenue and breakeven margin for the year. Management stresses it offers multi year margin improvement opportunities as the partnership matures. The contract adds a fresh revenue stream that is not dependent on existing membership trends and provides a platform to test and scale value based care initiatives. Early seasonality already contributed margin in the first quarter and the benefit is expected to grow as the partnership matures. The collaboration also enables shared investments in care management technologies that can further lower medical costs. The market may be overlooking this contract as a catalyst for sustainable earnings expansion beyond the current guidance period.
  • Clinical pathway expansion is progressing faster than disclosed with the congestive heart failure program now active in 90% of markets and driving inpatient diagnosis rates down from 25% to less than 5%. The COPD and dementia pathways are on track to be live in 50 to 70% of markets by the end of Q2 2026 and could generate claims based savings that would flow into 2026 profitability if the data materializes within the year. These programs reduce avoidable admissions and lower medical cost trend while enhancing quality scores that are tied to payer reimbursements. Better quality scores translate into higher bonus payments from Medicare Advantage plans and increase the attractiveness of the network to physicians. The early success of the heart failure initiative demonstrates the company’s ability to scale clinical protocols effectively across diverse geographies. The market may not be giving enough credit to the near term earnings contribution of these quality initiatives.
  • Artificial intelligence driven process improvements are showing early limited impact on operating expenses but are having a more pronounced effect on medical cost and revenue lines through better risk stratification and suspecting algorithms. Management indicated that the value from AI will become more visible later in health care cycles as data accumulates and models refine. This suggests that the current expense base may be overstated relative to the long term efficiency gains that AI will unlock. As AI models ingest more longitudinal claims data they can identify subtle patterns that precede costly events. Acting on these insights can shift care from reactive to preventive thereby reducing expensive hospitalizations. Investors could be missing the future margin expansion that AI enabled analytics will deliver.
  • The company’s ACO REACH segment benefited from a CMS adjustment that removed suspect urinary catheter and skin substitute costs from 2025 results delivering about five million dollars of upside in the quarter. While management noted this benefit relates to 2025 performance the underlying ability to identify and avoid fraudulent or low value claims reflects a stronger claims analytics capability that can be reapplied each year. This capability reduces unnecessary medical expense and improves the predictability of earnings. Strong claims analytics also supports better risk adjustment accuracy which can increase revenue without adding risk. The ability to continuously refine claim validation processes creates a defensible advantage in a regulatory environment focused on payment integrity. The market may be treating this as a one time boost rather than a sign of ongoing operational excellence.
▼ Bear case
  • Medicare Advantage membership fell to 426 thousand at quarter end down from 491 thousand a year earlier reflecting a measured growth strategy and market exits that have trimmed the top line. The decline in membership reduces the base for capitation revenue and puts pressure on the company to offset losses through higher risk scores or new contracts. Continued attrition could weigh on revenue growth and make it harder to achieve the revised full year revenue guidance of 5.7 to 5.8 billion dollars. The company’s reliance on in market growth alone limits its ability to replenish the member base through geographic expansion. Without new market entry the long term growth trajectory becomes more dependent on retaining existing physician partners. Any further loss of physician groups would exacerbate revenue pressure and could trigger a downward spiral in membership.
  • Paid claims visibility for 2026 remains limited early in the year leading the company to record a quarterly cost trend of 7.4% which is above the full year guidance of 7% and suggests underlying medical cost pressures may be stronger than anticipated. The reliance on conservative reserving for Part D costs due to limited data until third quarter reconciliation adds uncertainty to expense forecasts. If cost trends stay elevated the medical margin improvement seen in the quarter may not be sustainable. Elevated medical costs also pressure the ability to meet the modest adjusted EBITDA guidance range of 10 to 40 million dollars for the full year. The company has stated it will continue to take a prudent approach to Part D reserving which could result in higher than expected reserves if final reconciliations reveal larger liabilities. This reserve buildup would directly subtract from earnings and could lead to earnings surprises to the downside.
  • The company has stated it is not yet resuming offensive new market growth and is focusing on in market growth and execution amid dynamic industry conditions. This defensive posture limits the ability to replenish the membership base through geographic expansion and makes the business more dependent on retaining existing physician partners. Without new market entry the long term growth trajectory could be constrained especially as demographic growth alone may not offset churn. Physician partner retention is not guaranteed as competitive offers from other value based care platforms could lure away key groups. Loss of high performing physicians would diminish the network’s ability to deliver quality outcomes and could damage payer relationships. Such a scenario would undermine the company’s margin improvement thesis and could lead to revised downward guidance.
  • ACO REACH adjusted EBITDA came in five million dollars above expectations due to a CMS adjustment that removed suspect claims from 2025 results a benefit that management characterized as relating to prior year performance. This suggests that the upside may be non recurring and that the segment’s earnings could revert to historical levels once the adjustment lapses. The company’s reliance on such non recurring benefits creates uncertainty about the sustainability of ACO REACH earnings. If the CMS adjustment does not repeat in future periods the segment may need to rely solely on underlying operational performance. Historical ACO REACH performance has shown modest profitability with limited upside potential absent external adjustments. Investors who are counting on continued ACO REACH outperformance may be exposed to a potential earnings downgrade.
  • The upcoming 2027 CMS rate notice includes a 1.12% normalization factor that the company plans to offset through burden of illness quality and contracting initiatives but the effectiveness of these offsets remains unproven. Any shortfall in offsetting the normalization factor could pressure future reimbursement rates and compress margins. Additionally the company’s reliance on payer contracts to capture corridors and carve out supplemental benefits assumes a cooperative payer environment that could shift if payers tighten benefit designs or demand lower premiums. A shift in payer benefit design could reduce the upside from risk score improvements and limit the ability to generate additional revenue from supplemental services. The company has also disclosed limited exposure to unlinked chart review risk but any change in CMS audit methodology could increase compliance costs. Increased compliance costs would further erode medical margin and could offset any gains from clinical programs.

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Care Facilities
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 HCA HCA Healthcare, Inc. 87.94 Bn11.251.1548.02 Bn
2 CHE Chemed Corp 18.08 Bn51.687.120.09 Bn
3 THC Tenet Healthcare Corp 16.59 Bn9.740.7713.21 Bn
4 DVA Davita Inc. 15.37 Bn14.021.1010.63 Bn
5 EHC Encompass Health Corp 10.07 Bn654.201.662.57 Bn
6 ENSG Ensign Group, Inc 9.52 Bn27.181.810.14 Bn
7 UHS Universal Health Services Inc 9.19 Bn6.050.524.71 Bn
8 PACS PACS Group, Inc. 6.96 Bn28.551.280.05 Bn